Shares of Entero Therapeutics, Inc. (NASDAQ:ENTO – Get Free Report) were down 5.3% during mid-day trading on Tuesday . The stock traded as low as $0.37 and last traded at $0.40. Approximately 179,837 shares were traded during mid-day trading, a decline of 60% from the average daily volume of 452,608 shares. The stock had previously closed at $0.42.
Entero Therapeutics Trading Down 5.3%
The stock has a fifty day simple moving average of $0.44 and a two-hundred day simple moving average of $0.52.
Entero Therapeutics Company Profile
Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.
See Also
- Five stocks we like better than Entero Therapeutics
- Find and Profitably Trade Stocks at 52-Week Lows
- NVIDIA Stock Surges on Bullish News: How High Could It Climb?
- How to Calculate Inflation Rate
- Why Boeing May Be Ready to Take Off After Latest Developments
- What is Forex and How Does it Work?
- eBay Nears Big Breakout: Time to Buy the Under-the-Radar Winner?
Receive News & Ratings for Entero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
